The WILLOW LTE study with enpatoran in participants with SCLE, DLE and/or SLE

Prior treatment

• Received LTE prohibited medication during the WILLOW study or after the WILLOW study Week 24
• Participation in any other investigational drug study after the WILLOW study Week 24

Other illness

• Ongoing or active clinically significant viral (including Severe acute arespiratory syndrome coronavirus 2 [(SARS‑CoV‑2)], bacterial or fungal infection, or any major episode of infection requiring hospitalization

Lab values

• Participants who experienced serious event(s) related to the study intervention during the WILLOW study - Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with Long Term Extension (LTE) study participation

Other

• Other protocol defined exclusion criteria could apply

• Are ≥ 18 and ≤ 76 years of age at the time of signing the informed consent
• Are active SCLE, DLE and/or SLE that have completed the 24 week Treatment of the Willow Study
• Have a Body Mass Index (BMI) within the greater than or equal to (>=) 40 kilograms per meter square (inclusive) at Screening
• Participants who had successfully completed Week 48 of the Part 1 will have the opportunity to participate in the LTE Part 2. In exceptional cases and after Sponsor review, participants who have completed the Week 48 visit of the Part 1 within the previous 4-weeks may be considered for Part 2 participation based on eligibility review. Previous 4-weeks will be calculated from the Week 48 visit of Part 1
• Other protocol defined inclusion criteria could apply